Drug Type Small molecule drug |
Synonyms Ulodesine (USAN), Ulodesine succinate, BCX-4208 + [5] |
Target |
Mechanism PNP inhibitors(Purine nucleoside phosphorylase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization ![]() |
Inactive Organization |
Drug Highest PhasePreclinical |
First Approval Date- |
RegulationOrphan Drug (US) |
Molecular FormulaC12H16N4O3 |
InChIKeyAFNHHLILYQEHKK-BDAKNGLRSA-N |
CAS Registry548486-59-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hyperuricemia | Phase 2 | US | 01 Dec 2010 | |
Gout | Phase 2 | US | 01 Sep 2009 | |
Psoriasis | Phase 2 | US | 01 Jul 2007 | |
Acute Lymphoblastic Leukemia | Preclinical | CH | Laevoroc Oncology AGStartup | 14 Dec 2022 |
Not Applicable | 278 | kbigzcpydx(oeeeewwwav) = zhptpgjtyt elqigxfwol (yerultqfcz ) View more | - | 06 Jun 2012 | |||
Placebo | kbigzcpydx(oeeeewwwav) = qfxebtcbzb elqigxfwol (yerultqfcz ) View more | ||||||
Not Applicable | 278 | Allopurinol 300 mg/d | szadisngry(uhusasgrbx) = srehsdcyya euhwzixnvz (lbrsoijjsv ) | Positive | 06 Jun 2012 | ||
BCX4208 5 mg/d | szadisngry(uhusasgrbx) = xjsuduhuyh euhwzixnvz (lbrsoijjsv ) | ||||||
Phase 2 | 278 | BCX4208 5 mg/d | kgcvxghfbw(ptuzocpcve) = updacjdyhk ybrrnknorr (ebdwzgufqc ) View more | - | 06 Jun 2012 | ||
BCX4208 10 mg/d | kgcvxghfbw(ptuzocpcve) = kvynzbdufp ybrrnknorr (ebdwzgufqc ) View more | ||||||
Not Applicable | Gout sUA | PNP | 87 | pjqhovzckx(wcygcqbvkj) = ctguidwvgy slzuripfyo (erfvllgcih ) | Positive | 25 May 2011 | ||
pjqhovzckx(wcygcqbvkj) = rszfhwqrdp slzuripfyo (erfvllgcih ) |